Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay Popat

Showing results (151-160 of 273) with videos related to

Pageof 28
Sort By:
Cancer|October 28, 2008
Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapyAlex D Drilon, Sanjay Popat, Gauri Bhuchar, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?Marta Capelan, Desamparados Roda, Elena Geuna, et al.
JAMA Network Open|November 3, 2022
Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology AssessmentSreeram V Ramagopalan, Sanjay Popat, Alind Gupta, et al.
Cancers|July 29, 2023
A Subset of Non-Small Cell Lung Cancer Patients Treated with Pemetrexed Show <sup>18</sup>F-Fluorothymidine "Flare" on Positron Emission TomographyPreetha Aravind, Sanjay Popat, Tara D Barwick, et al.
Future Oncology (London, England)|May 24, 2022
Indirect comparisons of brigatinib and alectinib for front-line <i>ALK</i>-positive non-small-cell lung cancerKaren L Reckamp, Huamao M Lin, Holly Cranmer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 11, 2013
Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapySophie Papa, Sanjay Popat, Riyaz Shah, et al.
BMC Research Notes|November 20, 2015
Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practiceFatma Abdelraouf, Adam Sharp, Manisha Maurya, et al.
Molecular Cancer Therapeutics|April 3, 2022
Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic ChangesElizabeth A Coker, Adam Stewart, Bugra Ozer, et al.
The Lancet. Respiratory Medicine|March 23, 2020
Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trialGary Middleton, Kristian Brock, Joshua Savage, et al.
Future Oncology (London, England)|February 14, 2019
Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?Martin Reck, Keith M Kerr, Christian Grohé, et al.
Pageof 28

Showing results (151-160 of 273) with videos related to

Sort By:
Pageof 28
Cancer|October 28, 2008
Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapyAlex D Drilon, Sanjay Popat, Gauri Bhuchar, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?Marta Capelan, Desamparados Roda, Elena Geuna, et al.
JAMA Network Open|November 3, 2022
Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology AssessmentSreeram V Ramagopalan, Sanjay Popat, Alind Gupta, et al.
Cancers|July 29, 2023
A Subset of Non-Small Cell Lung Cancer Patients Treated with Pemetrexed Show <sup>18</sup>F-Fluorothymidine "Flare" on Positron Emission TomographyPreetha Aravind, Sanjay Popat, Tara D Barwick, et al.
Future Oncology (London, England)|May 24, 2022
Indirect comparisons of brigatinib and alectinib for front-line <i>ALK</i>-positive non-small-cell lung cancerKaren L Reckamp, Huamao M Lin, Holly Cranmer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 11, 2013
Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapySophie Papa, Sanjay Popat, Riyaz Shah, et al.
BMC Research Notes|November 20, 2015
Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practiceFatma Abdelraouf, Adam Sharp, Manisha Maurya, et al.
Molecular Cancer Therapeutics|April 3, 2022
Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic ChangesElizabeth A Coker, Adam Stewart, Bugra Ozer, et al.
The Lancet. Respiratory Medicine|March 23, 2020
Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trialGary Middleton, Kristian Brock, Joshua Savage, et al.
Future Oncology (London, England)|February 14, 2019
Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?Martin Reck, Keith M Kerr, Christian Grohé, et al.
Pageof 28